Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Equity Average (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Equity Average for 9 consecutive years, with $29.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 59.37% year-over-year to $29.7 million, compared with a TTM value of $29.7 million through Sep 2025, down 59.37%, and an annual FY2024 reading of $76.5 million, down 16.31% over the prior year.
  • Equity Average was $29.7 million for Q3 2025 at Spero Therapeutics, down from $33.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $125.4 million in Q1 2021 and bottomed at $29.7 million in Q3 2025.
  • Average Equity Average over 5 years is $70.0 million, with a median of $70.4 million recorded in 2023.
  • The sharpest move saw Equity Average surged 59.8% in 2021, then plummeted 66.16% in 2022.
  • Year by year, Equity Average stood at $100.1 million in 2021, then tumbled by 45.84% to $54.2 million in 2022, then soared by 48.13% to $80.3 million in 2023, then crashed by 30.49% to $55.8 million in 2024, then tumbled by 46.86% to $29.7 million in 2025.
  • Business Quant data shows Equity Average for SPRO at $29.7 million in Q3 2025, $33.3 million in Q2 2025, and $40.0 million in Q1 2025.